Navidea Biopharmaceuticals, Inc.
NAVBDelisted Jan 16, 2024- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000810509
Navidea Biopharmaceuticals, Inc. was delisted on Jan 16, 2024; its insiders filed their last Form 4 on Dec 5, 2023; 24 institutions reported holding it in 13F filings for Q3 2023, worth $225.8K in total; no superinvestor held it.
Q4 2021 vs. Q3 2021
How the institutions holding Navidea Biopharmaceuticals, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 29 | 31 | +2 |
| Shares | 1.58M | 1.68M | +106.8K (+6.8%) |
| Value | $2.76M | $1.68M | −$1.08M (−39.1%) |
New holders (5)
Institutions that held Navidea Biopharmaceuticals, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Commonwealth Equity Services, LLC | 51,203 | $51.0K | 0.00% |
| Virtu Financial LLC | 25,209 | $25.0K | 0.00% |
| Wolverine Trading, LLC | 12,484 | $13.0K | 0.00% |
| Northwestern Mutual Wealth Management Co | 237 | $0 | 0.00% |
| CoreCap Advisors, LLC | 45 | – | – |
Sold out (3)
Institutions that held Navidea Biopharmaceuticals, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Susquehanna International Group, LLP | 43,445 | $76.0K |
| HighTower Advisors, LLC | 28,465 | $48.0K |
| Jacobi Capital Management LLC | 1,000 | $2.00K |